AKT1 and plasma cell myeloma: Furthermore, PI3K/Akt inhibition by LY294002 pretreatment partially restored cell sensitivity to Bortezomib in TRIP13-OE myeloma cells, although LY294002 alone had slightly inhibitive effects (Figure 6I).